Skip to main content
. 2018 Aug 3;3(5):e000397. doi: 10.1136/esmoopen-2018-000397

Figure 4.

Figure 4

Proportion of patients showing clinically meaningful worsening, improvement or no change in perceived cognitive impairments for AAP versus ENZ at months 1, 2 and 3. *Worsening versus improvement or no change. AAP, abiraterone acetate plus prednisone; CI, confidence interval; ENZ, enzalutamide.

HHS Vulnerability Disclosure